Adial Pharmaceuticals, Inc.ADILNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank18
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P18
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -28.85% |
| Q2 2025 | -1.95% |
| Q1 2025 | 2.20% |
| Q4 2024 | -29.16% |
| Q3 2024 | 1.89% |
| Q2 2024 | 122.89% |
| Q1 2024 | 71.79% |
| Q4 2023 | 27.67% |
| Q3 2023 | -51.82% |
| Q2 2023 | 17.58% |
| Q1 2023 | -31.25% |
| Q4 2022 | -23.59% |
| Q3 2022 | 2.37% |
| Q2 2022 | 14.02% |
| Q1 2022 | -74.44% |
| Q4 2021 | 37.93% |
| Q3 2021 | -27.05% |
| Q2 2021 | 13.03% |
| Q1 2021 | -0.58% |
| Q4 2020 | 11.71% |
| Q3 2020 | 108.01% |
| Q2 2020 | -16.19% |
| Q1 2020 | -11.99% |
| Q4 2019 | 39.30% |
| Q3 2019 | -28.60% |
| Q2 2019 | 76.21% |
| Q1 2019 | 1342.46% |
| Q4 2018 | -74.73% |
| Q3 2018 | 145.05% |
| Q2 2018 | 38.53% |
| Q1 2018 | 6.81% |
| Q4 2017 | 86.97% |
| Q3 2017 | -51.96% |
| Q2 2017 | 30.10% |
| Q1 2017 | 59.26% |
| Q4 2016 | -31.80% |
| Q3 2016 | 7.31% |
| Q2 2016 | -2.42% |
| Q1 2016 | 0.00% |